|
Daily Medical Update
Idiopathic pulmonary fibrosis
Thursday, October 01, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
European respiratory review : an official journal of the European Respiratory Society (2026) - Systematic Review and Meta-Analysis
Key Findings
- Across 251 studies including 606,398 participants, pooled prevalence was 39% for systemic hypertension, 30% for dyslipidaemia, and 27% for gastro-oesophageal reflux disease.
- Lung cancer was the only comorbidity consistently associated with increased short-term and long-term mortality; few studies assessed links with quality of life or IPF progression.
📋 Practice Implication: IPF management should include structured assessment of cardiovascular, gastrointestinal, and malignant comorbidity burden, while recognizing that evidence linking most comorbidities to fibrosis progression remains limited.
|
BMC pulmonary medicine (2026) - Systematic Review and Meta-Analysis
Key Findings
- Among 35,807 patients across 33 studies, pooled GERD prevalence was 47.0% (95% CI 32.2%-62.0%).
- GERD prevalence increased when assessed with 24-hour esophageal pH monitoring compared with clinical records or non-reflux monitoring methods, and estimates varied substantially by study design, age, region, and sample size.
📋 Practice Implication: The high but heterogeneous GERD burden supports routine reflux symptom review and selective objective assessment in IPF, without treating the pooled prevalence as a uniform estimate for every patient.
|
BMC pulmonary medicine (2026) - Network Meta-Analysis and Systematic Review
Key Findings
- For FVC preservation versus placebo, recombinant human pentraxin-2, rentosertib, and nintedanib had the strongest statistical signals, with SMDs of 0.72, 0.63, and 0.50, respectively.
- No regimen significantly reduced all-cause mortality or showed clear adverse-event or serious-adverse-event differences versus placebo; comparative evidence was mostly low to very low certainty.
📋 Practice Implication: Treatment selection should remain anchored to established evidence and patient tolerance because exploratory comparative rankings do not yet establish a preferred combination strategy or mortality advantage.
|
The clinical respiratory journal (2026) - Systematic Review and Meta-Analysis
Key Findings
- Across four randomized trials involving 2,515 patients, nerandomilast attenuated FVC decline versus placebo by 69.25 mL (95% CI 52.1-86.29).
- Nerandomilast did not improve DLCO, while pooled all-cause mortality was lower (RR 0.68) without increased adverse events (RR 1.00) or serious adverse events (RR 0.93).
📋 Practice Implication: Nerandomilast is a promising lung-function-preserving therapy with reassuring pooled safety, but any mortality benefit should remain provisional because the individual trials were not powered for mortality outcomes.
|
Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace (2024) - Systematic Review and Meta-Analysis
Key Findings
- Among IPF patients with COVID-19, pooled mortality was 34% (95% CI 21%-48%), hospitalization was 36% (95% CI 10%-75%), and ICU admission was 31% (95% CI 7%-71%).
- Mortality, hospitalization, and ICU outcome estimates had low or very low certainty because of publication bias and heterogeneity across the six included studies.
📋 Practice Implication: COVID-19 prevention and prompt, individualized evaluation remain especially important in IPF, while the pooled hospitalization, ICU, and mortality estimates should be used as approximate risk signals rather than precise prognostic constants.
|
|
💡
Summary
Recent evidence highlights a substantial comorbidity burden in idiopathic pulmonary fibrosis, with gastroesophageal reflux disease and cardiovascular conditions common across clinical cohorts. Comparative treatment analyses support signals for preserving lung function with established and emerging antifibrotic approaches, but mortality and combination-therapy advantages remain uncertain; COVID-19 continues to carry high hospitalization and mortality risks in IPF.
|
|